MUC1 and Miyoshi myopathy: Frequency of presence of expression of the immune-oncological targets BAFFR, TACI, CD19, CD20, CD22 and CD37 significantly decreases, those for MUC1 and NY-ESO1 significantly increases from MGUS to AMM to MM to MMR as well as from AMM to MM to MMR.